Watertown, MA – According to filings with the U.S. Securities and Exchange Commission, Selecta Biosciences is raising $25,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Carsten Brunn played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Selecta Biosciences

Selecta Biosciences is a clinical-stage biotechnology company with an unrelenting commitment to overcoming immunogenicity with our pioneering ImmTOR immune tolerance platform. At our core, we are problem-solvers dedicated to transforming the lives of patients and their families who struggle with serious and debilitating diseases.

To learn more about Selecta Biosciences, visit http://www.selectabio.com/

Contact:
Carsten Brunn, President and Chief Executive Officer
617-923-1400
cbrunn@selectabio.com
https://www.linkedin.com/in/carsten-brunn-a8b287a/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved